Journal
JOURNAL OF CLINICAL MEDICINE
Volume 9, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/jcm9051256
Keywords
PARK7 (DJ-1); therapeutic target; apoptosis; redox sensor; chemoresistance
Categories
Funding
- National Research Foundation of Korea grant [2020R1A2C1012484]
- National Research Foundation of Korea [2020R1A2C1012484] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The expression of PARK7 is upregulated in various types of cancer, suggesting its potential role as a critical regulator of the pathogenesis of cancer and in the treatment of cancer and neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington disease. PARK7 activates various intracellular signaling pathways that have been implicated in the induction of tumor progression, which subsequently enhances tumor initiation, continued proliferation, metastasis, recurrence, and resistance to chemotherapy. Additionally, secreted PARK7 has been identified as a high-risk factor for the pathogenesis and survival of various cancers. This review summarizes the current understanding of the correlation between the expression of PARK7 and tumor progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
